An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients With Advanced Solid Tumors
This clinical trial is testing a new experimental medication called XL309, both by itself and combined with another cancer-fighting drug called olaparib. Researchers want to see if these treatments are safe and effective for adults with advanced solid tumors that have grown or spread.
You may be able to join if you are 18 or older, can still carry out your normal daily activities, and have healthy organs and blood cells. However, recent treatments like chemotherapy, radiation, or other targeted therapies within the last few weeks may mean you cannot participate.
As a participant, you will receive either the XL309 medication alone or in combination with olaparib. Doctors will closely monitor your health, how your body processes the medicine, and check for any side effects.
The study is currently recruiting volunteers and has locations in Fountain Valley, California, as well as Jacksonville and Orlando, Florida.
- 1Tests a new experimental medication called XL309 for advanced solid tumors.
- 2Study is currently recruiting patients at specific locations in California and Florida.
- 3Involves close medical monitoring to check for safety and effectiveness.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.